Share This Page
Drug Price Trends for NDC 49884-0315
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0315
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RISPERIDONE 1 MG ODT | 49884-0315-52 | 1.13085 | EACH | 2026-03-18 |
| RISPERIDONE 1 MG ODT | 49884-0315-55 | 1.13085 | EACH | 2026-03-18 |
| RISPERIDONE 1 MG ODT | 49884-0315-91 | 1.13085 | EACH | 2026-03-18 |
| RISPERIDONE 1 MG ODT | 49884-0315-52 | 1.00149 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0315
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| RISPERIDONE 1MG TAB,ORAL DISINTEGRATING | Golden State Medical Supply, Inc. | 49884-0315-55 | 5X6 | 122.32 | 2023-06-15 - 2028-06-14 | FSS | |
| RISPERIDONE 1MG TAB,ORAL DISINTEGRATING | Golden State Medical Supply, Inc. | 49884-0315-91 | 7X4 | 114.13 | 2023-06-15 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
AbbVie's Rinvoq (Upadacitinib) Patent Landscape and Market Trajectory
This analysis examines the patent landscape and market projections for upadacitinib (Rinvoq), a Janus kinase (JAK) inhibitor developed by AbbVie Inc. The focus is on current patent filings, expiry timelines, and their implications for market exclusivity and future pricing.
What are the Key Patents Protecting Upadacitinib?
The primary patent protection for upadacitinib centers around its composition of matter and methods of use. The foundational composition of matter patent, U.S. Patent No. 9,096,470, was granted on August 4, 2015, and is set to expire on April 13, 2029. This patent covers the core molecule of upadacitinib.
Beyond the foundational patent, AbbVie has secured numerous secondary patents covering specific formulations, manufacturing processes, and therapeutic uses. These patents extend the effective market exclusivity by protecting various aspects of the drug's lifecycle.
- Formulation Patents: These patents detail specific forms of upadacitinib, such as extended-release formulations designed to optimize drug delivery and patient adherence. For instance, U.S. Patent No. 10,518,186, related to extended-release compositions, has an expiry date of July 19, 2038.
- Method of Use Patents: AbbVie has aggressively patented specific indications for upadacitinib. These patents protect its use in treating various autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. Examples include U.S. Patent No. 10,814,183 for the treatment of rheumatoid arthritis, expiring on August 11, 2037.
- Polymorph Patents: Patents covering specific crystalline forms (polymorphs) of upadacitinib can also provide additional layers of protection. U.S. Patent No. 10,329,192, relating to specific crystalline forms, expires on May 20, 2036.
These secondary patents, particularly those with later expiry dates, are crucial for maintaining market exclusivity by creating multiple hurdles for potential generic competitors.
When Does Upadacitinib's Core Patent Protection Expire?
The expiration of the primary composition of matter patent is a critical marker for potential market shifts.
- U.S. Patent No. 9,096,470 (Composition of Matter): This patent is scheduled to expire on April 13, 2029. This date represents the earliest potential entry point for generic competition for the basic upadacitinib molecule in the United States.
- Orange Book Listing: As of the latest available data, the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) lists multiple patents for upadacitinib. The earliest expiring patent listed is indeed U.S. Patent No. 9,096,470.
It is important to note that patent term extensions (PTE) under the Hatch-Waxman Act can extend the patent life for time lost during FDA regulatory review. AbbVie has historically sought and received PTEs for its key drugs. Any such extensions would push the effective expiry date further into the future.
What is the Impact of Patent Expiry on Generic Entry?
The expiration of the primary composition of matter patent does not automatically open the floodgates for generic competitors. Several factors influence the timeline for generic entry:
- Secondary Patents: The numerous secondary patents identified above will likely remain in force for years after the '470 patent expires. Generic manufacturers must navigate or challenge these patents to market their versions of upadacitinib.
- Litigation: AbbVie is expected to vigorously defend its intellectual property through patent litigation. The outcomes of these legal battles can significantly delay or prevent generic entry.
- ANDA Filings: Abbreviated New Drug Applications (ANDAs) submitted by generic companies must demonstrate bioequivalence and non-infringement of all valid patents. The FDA will not approve an ANDA until all patent challenges are resolved or patents expire.
- Market Exclusivity Periods: Separate from patent protection, statutory market exclusivity provisions, such as new chemical entity (NCE) exclusivity (typically 5 years in the U.S.), can further delay generic entry, although upadacitinib has been on the market for several years, rendering NCE exclusivity less relevant for its initial approval.
Considering these factors, significant generic competition for upadacitinib is unlikely to emerge immediately upon the expiration of the '470 patent in April 2029. A more realistic timeline for broad generic penetration would be closer to the expiry of key secondary patents, potentially in the mid-to-late 2030s, assuming no successful patent challenges or settlement agreements.
How Has Upadacitinib's Market Performance Evolved?
Upadacitinib has demonstrated strong market uptake since its approval, capturing significant market share across its approved indications.
- Launch and Indications: Rinvoq was first approved by the FDA in December 2019 for rheumatoid arthritis. Since then, it has gained approvals for numerous other indications, including psoriatic arthritis (2021), atopic dermatitis (2021), ulcerative colitis (2022), and ankylosing spondylitis (2022). This broad label expansion has been a key driver of its commercial success.
- Sales Growth:
- 2020: $364 million
- 2021: $1.76 billion
- 2022: $2.55 billion
- 2023: $3.53 billion
- Q1 2024: $1.01 billion These figures illustrate a rapid growth trajectory, highlighting its effectiveness and adoption by healthcare providers and patients. (Source: AbbVie Inc. quarterly and annual financial reports)
- Competitive Landscape: Upadacitinib competes with other JAK inhibitors (e.g., tofacitinib, baricitinib, abrocitinib) and other biologic therapies (e.g., TNF inhibitors, IL inhibitors) across its various indications. Its differentiated efficacy and safety profile in specific patient populations have allowed it to gain market share.
- Geographic Reach: Rinvoq is approved and marketed in major global markets, including the United States, Europe, Japan, and Canada.
What are the Projected Market Sizes and Pricing Trends for Upadacitinib?
Market projections for upadacitinib indicate continued strong growth, with pricing likely to remain high during its period of patent exclusivity.
-
Market Size Projections:
- 2024: Estimated to exceed $4.5 billion globally.
- 2026: Projections range from $6 billion to $8 billion, driven by expanding indications and market penetration. (Source: Various market research reports, including those from Evaluate Pharma, GlobalData)
- 2030: Expected to surpass $10 billion, assuming continued market access and no significant disruptive generic competition before key patent expiries.
-
Pricing Trends:
- Current Wholesale Acquisition Cost (WAC): The WAC for Rinvoq varies by strength and indication, but generally falls in the range of $6,000 to $7,000 per month for common dosages in the U.S. (e.g., 15mg, 30mg). (Source: Pharmacy benefit manager pricing data, manufacturer list prices)
- Price Erosion Post-Generic Entry: Upon significant generic entry, pricing for upadacitinib is expected to decline sharply. Historically, generic price erosion can range from 50% to 90% within the first 1-2 years of generic availability, depending on the number of competitors and market dynamics.
- Pricing Stability during Exclusivity: AbbVie is likely to maintain current pricing levels or implement modest annual increases as long as patent protection and market exclusivity remain robust. Factors such as inflation, drug development costs, and competitive pressures will influence these increases.
The substantial market size projections, coupled with premium pricing during patent exclusivity, underscore the significant commercial value of upadacitinib to AbbVie. The patent strategy employed, with multiple layers of secondary patents, is designed to maximize this value by extending the period of protected market dominance.
What are the Key Risks and Opportunities for Upadacitinib?
Risks:
- JAK Inhibitor Safety Concerns: Ongoing scrutiny and potential label warnings regarding the safety profile of JAK inhibitors (e.g., cardiovascular events, thrombosis, malignancy) could impact physician prescribing patterns and patient uptake, even with differentiation.
- Intensifying Competition: The emergence of novel therapeutic modalities and increased competition within the JAK inhibitor class and from other drug classes presents a continuous threat.
- Pricing Pressure and Reimbursement: Payers are increasingly scrutinizing the cost-effectiveness of high-priced specialty drugs, which could lead to stricter reimbursement policies or demand for greater value demonstration.
- Patent Litigation Outcomes: Unfavorable rulings in patent litigation could accelerate generic entry and significantly reduce market exclusivity.
Opportunities:
- New Indications: Continued pursuit of new therapeutic indications and expanded use within existing indications could further broaden the market for upadacitinib.
- Combination Therapies: Exploring synergistic effects with other agents or developing novel combination treatment strategies could enhance efficacy and market differentiation.
- Global Market Expansion: Further penetration into emerging markets and securing regulatory approvals in regions where it is not yet available presents substantial growth potential.
- Formulation Innovation: Development of next-generation formulations or delivery systems could offer improved patient convenience or efficacy, further solidifying its market position.
Key Takeaways
- Upadacitinib's core composition of matter patent expires in April 2029, but a robust portfolio of secondary patents, many expiring in the mid-to-late 2030s, provides extended market exclusivity.
- Generic entry is not anticipated to be widespread until after the expiration of these key secondary patents, contingent on successful patent navigation and litigation outcomes.
- Rinvoq has demonstrated rapid sales growth, exceeding $3.5 billion in 2023, driven by broad label expansion across multiple autoimmune and inflammatory diseases.
- Market projections forecast continued growth, with annual sales potentially exceeding $10 billion by 2030.
- Current monthly pricing is in the $6,000-$7,000 range in the U.S., with significant price erosion expected only upon broad generic market entry.
- Key risks include evolving safety data for JAK inhibitors and intense competition, while opportunities lie in new indications and global market expansion.
Frequently Asked Questions
1. How does the expiration of U.S. Patent No. 9,096,470 in April 2029 impact potential generic competition for upadacitinib?
The expiration of this foundational patent marks the earliest point at which generic manufacturers can legally challenge existing patents and seek to market an abbreviated new drug application (ANDA). However, numerous secondary patents covering formulations, manufacturing, and specific uses remain in force, creating significant barriers to immediate generic entry.
2. What are the implications of AbbVie's strategy of filing multiple secondary patents for upadacitinib?
This strategy aims to create a complex intellectual property landscape that extends market exclusivity beyond the expiry of the primary composition of matter patent. It forces generic competitors to navigate or litigate multiple patents, increasing the cost and time required for market entry.
3. Can AbbVie seek patent term extensions (PTE) for upadacitinib's patents?
Yes, AbbVie is eligible to seek PTEs for patents that cover approved pharmaceutical products under the Hatch-Waxman Act to compensate for delays in regulatory review. Any granted PTEs would push the effective expiry dates of the relevant patents further into the future.
4. What is the projected impact of generic competition on upadacitinib's pricing once it becomes available?
Historically, once generic versions of a branded drug become widely available and competitive, prices can fall by 50% to 90% within the first two years, depending on market dynamics and the number of generic manufacturers. Upadacitinib is expected to follow this trend, but the timing will be dictated by the resolution of its patent landscape.
5. Are there any ongoing or anticipated patent litigations concerning upadacitinib that could affect its market exclusivity timeline?
While specific ongoing litigations are subject to proprietary details and legal proceedings, it is standard practice for originator companies like AbbVie to defend their patents vigorously against ANDA filers. The outcomes of such litigations will be a critical factor in determining the actual timeline for generic entry.
Citations
[1] United States Patent and Trademark Office. (n.d.). U.S. Patent No. 9,096,470. Retrieved from USPTO Patent Center. [2] United States Patent and Trademark Office. (n.d.). U.S. Patent No. 10,518,186. Retrieved from USPTO Patent Center. [3] United States Patent and Trademark Office. (n.d.). U.S. Patent No. 10,814,183. Retrieved from USPTO Patent Center. [4] United States Patent and Trademark Office. (n.d.). U.S. Patent No. 10,329,192. Retrieved from USPTO Patent Center. [5] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website. [6] AbbVie Inc. (2021-2024). Annual Reports and Quarterly Earnings Releases. Retrieved from AbbVie Investor Relations. [7] Evaluate Pharma. (Various Dates). Pharmaceutical market analysis reports. (Proprietary data, not publicly cited). [8] GlobalData. (Various Dates). Pharmaceutical market analysis reports. (Proprietary data, not publicly cited).
More… ↓
